<SEC-DOCUMENT>0000947871-23-000866.txt : 20230815
<SEC-HEADER>0000947871-23-000866.hdr.sgml : 20230815
<ACCEPTANCE-DATETIME>20230815182547
ACCESSION NUMBER:		0000947871-23-000866
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230815
DATE AS OF CHANGE:		20230815

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galecto, Inc.
		CENTRAL INDEX KEY:			0001800315
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				371957007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39655
		FILM NUMBER:		231176055

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		45-70-70-52-10

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galecto Inc.
		DATE OF NAME CHANGE:	20200116

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OrbiMed Advisors Israel II Ltd
		CENTRAL INDEX KEY:			0001682093
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		212-739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: OrbiMed Advisors Israel II Ltd -->
          <cik>0001682093</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001800315</issuerCik>
      <issuerName>Galecto, Inc.</issuerName>
      <secFileNumber>001-39655</secFileNumber>
      <issuerAddress>
        <com:street1>75 State Street</com:street1>
        <com:street2>Suite 100</com:street2>
        <com:city>Boston</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02109</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>45-70-70-52-10</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Israel Partners II, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Bank of America</name>
        <address>
          <com:street1>One Bryant Park</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10036</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>489970</noOfUnitsSold>
      <aggregateMarketValue>367478.00</aggregateMarketValue>
      <noOfUnitsOutstanding>25673474</noOfUnitsOutstanding>
      <approxSaleDate>08/15/2023</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>10/23/2018</acquiredDate>
      <natureOfAcquisitionTransaction>Private placement</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>489970</amountOfSecuritiesAcquired>
      <paymentDate>10/23/2018</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>OrbiMed Israel Partners II, L.P.</name>
        <address>
          <com:street1>5 Hahoshlim St.</com:street1>
          <com:street2>Building B, 1st Floor</com:street2>
          <com:city>Herzliya Pituach</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>4672405</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>07/13/2023</saleDate>
      <amountOfSecuritiesSold>52800</amountOfSecuritiesSold>
      <grossProceeds>126720.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>OrbiMed Israel Partners II, L.P.</name>
        <address>
          <com:street1>5 Hahoshlim St.</com:street1>
          <com:street2>Building B, 1st Floor</com:street2>
          <com:city>Herzliya Pituach</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>4672405</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>07/25/2023</saleDate>
      <amountOfSecuritiesSold>4700</amountOfSecuritiesSold>
      <grossProceeds>13724.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>OrbiMed Israel Partners II, L.P.</name>
        <address>
          <com:street1>5 Hahoshlim St.</com:street1>
          <com:street2>Building B, 1st Floor</com:street2>
          <com:city>Herzliya Pituach</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>4672405</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>07/31/2023</saleDate>
      <amountOfSecuritiesSold>29700</amountOfSecuritiesSold>
      <grossProceeds>89100.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>OrbiMed Israel GP II, L.P. is the general partner of OrbiMed Israel Partners II, L.P. OrbiMed Advisors Israel II Limited is the general partner of OrbiMed Israel GP II, L.P.</remarks>
    <noticeSignature>
      <noticeDate>08/15/2023</noticeDate>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors II Limited, general partner of the general partner of OrbiMed Israel Partners II, L.P.</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
